Lophora is a drug-development start-up focusing on central nervous system diseases including treatment-resistant depression. Founded in 2018 Lophora has successfully finished initial characterization of its lead-candidate through funding granted by the BioInovation Institute (Novo Nordisk Foundation) and plan to begin first-in-human trials by 2022. The company has identified and patented a new class of proprietary ligands that has a similar pharmacological profile as psilocybin, which has shown promising clinical results in the treatment of depression. Lophora is currently focusing on Treatment-Resistant Depression, but clinical data suggests that the new drug class will also be applicable to the treatment of anxiety, PTSD and substance abuse. Lophora holds a unique position in the market for anti-depressant therapies of the future. The company seeks to mature lead-candidate LPH-5 through pre-clinical operations, toward IND status by the end of 2021. Given our unique technology and knowledge of the field, we are confident that we are moving ahead of a global market shift towards Psychedelic-assisted Therapy as a treatment for CNS disorders.